creatine has been researched along with Chronic Progressive Multiple Sclerosis in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute secondary progressive multiple sclerosis (SPMS) is characterized by escalating neurological disability, with limited disease-modifying therapeutic options." | 5.72 | Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report. ( Jezdimirovic, T; Ostojic, J; Ostojic, SM; Stajer, V; Zanini, D, 2022) |
| " Concentrations of glutamate + glutamin (Glx), cholin (Cho), myoinositol (mIns), N-acetyl aspartate (NAA) expressed as ratio with creatine (Cr) and NAA were correlated with markers of disease activity (RIO score), Multiple Sclerosis Severity Scale (MSSS), Depressive-Severity Status Scale and Simple Numerical Fatigue Scale." | 3.85 | Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue. ( Baranovičová, E; Bittšanský, M; Čierny, D; Hnilicová, P; Kantorová, E; Kurča, E; Nosáľ, V; Poláček, H; Sivák, Š; Zeleňák, K, 2017) |
| "Acute secondary progressive multiple sclerosis (SPMS) is characterized by escalating neurological disability, with limited disease-modifying therapeutic options." | 1.72 | Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report. ( Jezdimirovic, T; Ostojic, J; Ostojic, SM; Stajer, V; Zanini, D, 2022) |
| "Patients with primary progressive multiple sclerosis have few lesions on conventional MRI, suggesting that changes in normal appearing white matter (NAWM), such as axonal loss, may be particularly relevant to disease progression in this group." | 1.30 | 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. ( Barker, GJ; Davie, CA; Leary, SM; Miller, DH; Parker, GJ; Stevenson, VL; Thompson, AJ; Wang, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostojic, SM | 1 |
| Ostojic, J | 1 |
| Zanini, D | 1 |
| Jezdimirovic, T | 1 |
| Stajer, V | 1 |
| Kantorová, E | 1 |
| Poláček, H | 1 |
| Bittšanský, M | 1 |
| Baranovičová, E | 1 |
| Hnilicová, P | 1 |
| Čierny, D | 1 |
| Sivák, Š | 1 |
| Nosáľ, V | 1 |
| Zeleňák, K | 1 |
| Kurča, E | 1 |
| Zeller, D | 1 |
| aufm Kampe, K | 1 |
| Biller, A | 1 |
| Stefan, K | 1 |
| Gentner, R | 1 |
| Schütz, A | 1 |
| Bartsch, A | 1 |
| Bendszus, M | 1 |
| Toyka, KV | 1 |
| Rieckmann, P | 1 |
| Classen, J | 1 |
| Pan, JW | 1 |
| Coyle, PK | 1 |
| Bashir, K | 1 |
| Whitaker, JN | 1 |
| Krupp, LB | 1 |
| Hetherington, HP | 1 |
| Sijens, PE | 1 |
| Mostert, JP | 1 |
| Oudkerk, M | 1 |
| De Keyser, J | 1 |
| Sajja, BR | 1 |
| Narayana, PA | 1 |
| Wolinsky, JS | 1 |
| Ahn, CW | 1 |
| Leary, SM | 1 |
| Davie, CA | 1 |
| Parker, GJ | 1 |
| Stevenson, VL | 1 |
| Wang, L | 1 |
| Barker, GJ | 1 |
| Miller, DH | 1 |
| Thompson, AJ | 1 |
| Suhy, J | 1 |
| Rooney, WD | 1 |
| Goodkin, DE | 1 |
| Capizzano, AA | 1 |
| Soher, BJ | 1 |
| Maudsley, AA | 1 |
| Waubant, E | 1 |
| Andersson, PB | 1 |
| Weiner, MW | 1 |
| Mader, I | 1 |
| Roser, W | 1 |
| Kappos, L | 1 |
| Hagberg, G | 1 |
| Seelig, J | 1 |
| Radue, EW | 1 |
| Steinbrich, W | 1 |
| Pozdniakov, AV | 1 |
| Tiutin, LA | 1 |
| Bisaga, GN | 1 |
| Odinak, MM | 1 |
2 trials available for creatine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study.
Topics: Aspartic Acid; Brain; Choline; Creatine; Glatiramer Acetate; Humans; Immunosuppressive Agents; Longi | 2008 |
Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study.
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Female; Follow-Up Studies; Guanidines; Humans; Image | 2000 |
8 other studies available for creatine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report.
Topics: Creatine; Female; Glycine; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Multiple Sclerosis; | 2022 |
Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue.
Topics: Adult; Aging; Aspartic Acid; Case-Control Studies; Choline; Creatine; Cross-Sectional Studies; Depre | 2017 |
Rapid-onset central motor plasticity in multiple sclerosis.
Topics: Adult; Aspartic Acid; Creatine; Cross-Sectional Studies; Female; Humans; Learning; Male; Middle Aged | 2010 |
Metabolic differences between multiple sclerosis subtypes measured by quantitative MR spectroscopy.
Topics: Aspartic Acid; Brain; Choline; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; Male; Mult | 2002 |
(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Energy Metabolism; Female; Humans; Image Processing, | 2006 |
1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis.
Topics: Adult; Aspartic Acid; Brain; Cohort Studies; Creatine; Dipeptides; Humans; Magnetic Resonance Spectr | 1999 |
1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
Topics: Adult; Aspartic Acid; Brain; Creatine; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonanc | 2000 |
[Proton magnetic-resonance spectroscopy in remitting and secondary-progressive multiple sclerosis].
Topics: Adolescent; Adult; Aspartic Acid; Brain; Choline; Creatine; Demyelinating Diseases; Female; gamma-Am | 2001 |